Spots Global Cancer Trial Database for Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy
Official Title: Sorafenib Treatment Modalities for HEpatoceLLular Carcinoma Patients in ItAly
Study ID: NCT01539681
Conditions
Interventions
Study Description
Brief Summary: Prospective, non-interventional, multi-center study. Patients affected by Hepatocellular Carcinoma (HCC) who are candidates for systemic therapy and in whom a decision to treat with sorafenib has been made. Aim of this non-interventional, post-marketing study is to evaluate the efficacy of sorafenib in terms of overall survival rate at 12 months in patients with HCC under daily-life treatment conditions.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Many Locations, , Italy
Contact Details
Name: Bayer Study Director
Affiliation: Bayer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
